Drug Patents owned by Merck Sharp Dohme

1. Drug name - BELSOMRA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7951797 MERCK SHARP DOHME Substituted diazepan orexin receptor antagonists
Nov, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10098892 MERCK SHARP DOHME Solid dosage formulations of an orexin receptor antagonist
May, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
M Jan 29, 2023

Drugs and Companies using SUVOREXANT ingredient

Market Authorisation Date: 13 August, 2014

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

2. Drug name - CLARINEX D 24 HOUR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6979463 MERCK SHARP DOHME Stable extended release oral dosage composition
Mar, 2022

(8 months ago)

US7820199 MERCK SHARP DOHME Stable extended release oral dosage composition
Mar, 2022

(8 months ago)

US7820199

(Pediatric)

MERCK SHARP DOHME Stable extended release oral dosage composition
Sep, 2022

(2 months ago)

Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient

Market Authorisation Date: 03 March, 2005

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;240MG TABLET, EXTENDED RELEASE;ORAL Discontinued

3. Drug name - DUTREBIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820660 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(4 months from now)

US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(9 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(a month ago)

US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(a month ago)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(4 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(4 months from now)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 3 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(6 years from now)

Drugs and Companies using LAMIVUDINE; RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 06 February, 2015

Treatment: Treatment of hiv-1 infection

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
150MG;EQ 300MG BASE TABLET;ORAL Discontinued

4. Drug name - ISENTRESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7169780 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2023

(9 months from now)

US7754731 MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Mar, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7217713 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(a month ago)

US7435734 MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Oct, 2022

(a month ago)

US7435734

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(4 months from now)

US7217713

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2023

(4 months from now)

US7169780

(Pediatric)

MERCK SHARP DOHME N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
Apr, 2024

(1 year, 3 months from now)

US7754731

(Pediatric)

MERCK SHARP DOHME Potassium salt of an HIV integrase inhibitor
Sep, 2029

(6 years from now)

US9649311 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Oct, 2030

(7 years from now)

US9649311

(Pediatric)

MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Apr, 2031

(8 years from now)

US10772888 MERCK SHARP DOHME Solid pharmaceutical compositions containing an integrase inhibitor
Mar, 2032

(9 years from now)

Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient

Market Authorisation Date: 21 December, 2011

Treatment: Treatment of hiv infection; Treatment of hiv-1 infection

Dosage: TABLET, CHEWABLE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET, CHEWABLE;ORAL Prescription
EQ 100MG BASE TABLET, CHEWABLE;ORAL Prescription

5. Drug name - JANUMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US8414921 MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jul, 2028

(5 years from now)

US8414921

(Pediatric)

MERCK SHARP DOHME Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
Jan, 2029

(6 years from now)

Exclusivity Exclusivity Expiration
M Aug 12, 2022
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 30 March, 2007

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET;ORAL Prescription
500MG;EQ 50MG BASE TABLET;ORAL Prescription

6. Drug name - JANUMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Dec 4, 2023
Pediatric Exclusivity (PED) Jun 4, 2024

Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 02 February, 2012

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
1GM;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 100MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 50MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

7. Drug name - JANUVIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
M Dec 4, 2023
Pediatric Exclusivity (PED) Feb 12, 2023

Drugs and Companies using SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 16 October, 2006

Treatment: Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 25MG BASE TABLET;ORAL Prescription
EQ 50MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription

8. Drug name - JUVISYNC

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8168637 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment of diabetes
Jun, 2022

(5 months ago)

US7125873 MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7125873

(Pediatric)

MERCK SHARP DOHME Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Oct, 2026

(3 years from now)

Drugs and Companies using SIMVASTATIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 07 October, 2011

Treatment: Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a ppar-gamma agonist (such as pioglitazone and rosiglitazone); Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with a sulfonylurea (such as glipizide, glimepiride and glyburide); Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with metformin; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and simvastatin is appropriate, in combination with insulin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
10MG;EQ 50MG BASE TABLET;ORAL Discontinued
10MG;EQ 100MG BASE TABLET;ORAL Discontinued
20MG;EQ 50MG BASE TABLET;ORAL Discontinued
20MG;EQ 100MG BASE TABLET;ORAL Discontinued
40MG;EQ 50MG BASE TABLET;ORAL Discontinued
40MG;EQ 100MG BASE TABLET;ORAL Discontinued

9. Drug name - NOXAFIL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8410077 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9750822 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US10117951 MERCK SHARP DOHME Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(6 years from now)

US9358297 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jun, 2031

(8 years from now)

US9023790 MERCK SHARP DOHME Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin
Jul, 2031

(8 years from now)

US9493582 MERCK SHARP DOHME Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) May 31, 2024
Orphan Drug Exclusivity (ODE) Jun 17, 2028
New Indication (I) Jun 17, 2024

Drugs and Companies using POSACONAZOLE ingredient

Market Authorisation Date: 13 March, 2014

Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; Prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Prophylaxis of invasive aspergillus and candida infections

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
300MG/16.7ML (18MG/ML) SOLUTION;INTRAVENOUS Prescription

10. Drug name - PREVYMIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 5 months from now)

USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(1 year, 5 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 8, 2024
New Chemical Entity Exclusivity (NCE) Nov 8, 2022

Drugs and Companies using LETERMOVIR ingredient

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
240MG/12ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription
480MG/24ML (20MG/ML) SOLUTION;INTRAVENOUS Prescription

11. Drug name - SEGLUROMET

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9439902 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET;ORAL Prescription
2.5MG;500MG TABLET;ORAL Prescription
7.5MG;1GM TABLET;ORAL Prescription
7.5MG;500MG TABLET;ORAL Prescription

12. Drug name - STEGLATRO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN ingredient

Market Authorisation Date: 19 December, 2017

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription

13. Drug name - STEGLUJAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6699871 MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jul, 2022

(4 months ago)

US7326708 MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
Nov, 2026

(3 years from now)

US8080580 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Jul, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6699871

(Pediatric)

MERCK SHARP DOHME Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
Jan, 2023

(a month from now)

US7326708

(Pediatric)

MERCK SHARP DOHME Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
May, 2027

(4 years from now)

US9439901 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

US9308204 MERCK SHARP DOHME Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
Oct, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Dec 19, 2022
M Sep 17, 2024

Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient

Market Authorisation Date: 19 December, 2017

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 100MG BASE TABLET;ORAL Prescription
15MG;EQ 100MG BASE TABLET;ORAL Prescription

14. Drug name - TEMODAR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8623868 MERCK SHARP DOHME Processes of making and using pharmaceutical formulations of antineoplastic agents
Feb, 2023

(2 months from now)

US7786118 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents
Feb, 2023

(2 months from now)

US6987108 MERCK SHARP DOHME Pharmaceutical formulations of antineoplastic agents and processes of making and using the same
Sep, 2023

(8 months from now)

Drugs and Companies using TEMOZOLOMIDE ingredient

Market Authorisation Date: 27 February, 2009

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
100MG/VIAL POWDER;INTRAVENOUS Prescription

15. Drug name - VERQUVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10736896 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US8420656 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921377 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US11439642 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

US9993476 MERCK SHARP DOHME Substituted 5-flouro-1H-pyrazolopyridines and their use
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 19, 2026

Drugs and Companies using VERICIGUAT ingredient

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

16. Drug name - VICTRELIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE43298 MERCK SHARP DOHME Peptides as NS3-serine protease inhibitors of hepatitis C virus
Dec, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8119602 MERCK SHARP DOHME Administration of HCV protease inhibitors in combination with food to improve bioavailability
Mar, 2027

(4 years from now)

US7772178 MERCK SHARP DOHME Pharmaceutical formulations and methods of treatment using the same
Nov, 2027

(4 years from now)

Drugs and Companies using BOCEPREVIR ingredient

Market Authorisation Date: 13 May, 2011

Treatment: Treatment of chronic hepatitis c (chc) genotype 1 infection, administered with food; Treatment of chronic hepatitis c (chc) genotype 1 infection in combination with peginterferon alfa and ribavirin in adult patients (>=18 years of age) with compensated liver disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
200MG CAPSULE;ORAL Discontinued

17. Drug name - WELIREG

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

US9908845 MERCK SHARP DOHME Aryl ethers and uses thereof
Sep, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 13, 2026
Orphan Drug Exclusivity (ODE) Aug 13, 2028

Drugs and Companies using BELZUTIFAN ingredient

Market Authorisation Date: 13 August, 2021

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
40MG TABLET;ORAL Prescription

18. Drug name - ZEPATIER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7973040 MERCK SHARP DOHME Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
Jul, 2029

(6 years from now)

US8871759 MERCK SHARP DOHME Inhibitors of hepatitis C virus replication
May, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Dec 9, 2024

Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient

Market Authorisation Date: 28 January, 2016

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG;100MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in